The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.
about
Agalsidase alfa: a review of its use in the management of Fabry diseaseFabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.The prevalence and epidemiology of genetic renal disease amongst adults with chronic kidney disease in Australia.Dysregulated autophagy contributes to podocyte damage in Fabry's disease.Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies.Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysisEffects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry diseaseMulticenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease.Altered dynamics of a lipid raft associated protein in a kidney model of Fabry diseasePatients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages.Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry disease.The Coexistence of Multiple Myeloma-associated Amyloid Light-chain Amyloidosis and Fabry Disease in a Hemodialysis PatientLong-term outcomes with agalsidase alfa enzyme replacement therapy: Analysis using deconstructed composite events.
P2860
Q28274194-95BEA022-FDBE-4D99-90DF-3EA40AD279B9Q33645550-CEB0368E-8FD8-4A5C-A233-A10CB4F057ECQ33776219-69C6F783-A3FF-402F-B0E2-4AB93334E1D1Q33858105-0275B791-89C1-4726-9D4B-CA69338BAAC4Q34730562-90221206-9B5B-4372-89AD-CC57E7017508Q36309032-4ABBCDDE-928F-4464-BF8F-34629D003A6FQ36571559-ED6822B3-BF94-462A-924C-9562094CBD82Q36590934-11C178BC-13B6-4F84-A639-F89FF7E25B2CQ37054755-0ECB42E9-3449-4A58-9227-0E5C98FBC106Q37624954-28EE666D-9E47-4B17-BA57-BFB3B26E14E2Q37670334-FE6DE0D6-9A87-4370-B3B5-962B763B41DCQ38184922-40E51192-B03E-4543-9219-33EC4705F993Q39344648-FBEF95AF-3AE9-404B-B07C-22B9AB951879Q42223734-6C48E84C-8553-496D-AAA3-73CD0907E13DQ47118738-58F8F359-76B2-41AC-A4B3-55605B948625
P2860
The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The effectiveness of long-term ...... reatment of Fabry nephropathy.
@ast
The effectiveness of long-term ...... reatment of Fabry nephropathy.
@en
type
label
The effectiveness of long-term ...... reatment of Fabry nephropathy.
@ast
The effectiveness of long-term ...... reatment of Fabry nephropathy.
@en
prefLabel
The effectiveness of long-term ...... reatment of Fabry nephropathy.
@ast
The effectiveness of long-term ...... reatment of Fabry nephropathy.
@en
P2093
P2860
P356
P1476
The effectiveness of long-term ...... treatment of Fabry nephropathy
@en
P2093
FOS Investigators
Joan Torras
Markus Cybulla
Michael West
Sandro Feriozzi
P2860
P356
10.2215/CJN.03130411
P577
2012-01-01T00:00:00Z